| abstract |
A composition comprising cells expressing a chimeric antigen receptor (CAR) for use in treating a tumor or cancer in a subject, wherein the treatment comprises administering the cells to the subject in a first and a consecutive dose, wherein : the first dose comprises no more than about 1 x 106 CAR-expressing cells per kilogram of subject body weight, no more than about 1 x 108 CAR-expressing cells, and/or no more than about 1 x 108 of CAR-expressing cells/m2 of the subject, and wherein the first dose is for administration at a time when the subject has morphological disease, and the consecutive dose is for administration at a time (i) that is more from about 14 days after and less than about 28 days after administration of the first dose and (ii) when the subject shows no morphological disease, and wherein the consecutive dose comprises an increased number of cells expressing CAR compared to the first dose. |